TOKYO -- Takeda Pharmaceutical has suspended the development of a plasma therapy for COVID-19 after it failed to show effectiveness in clinical trials, according to a Tuesday disclosure to investors.
Coronavirus
Takeda halts development of COVID-19 plasma therapy
Japanese drugmaker had counted on technology boost from Shire acquisition
A nurse attends to a patient suffering from COVID-19 at a hospital in Spain. © Reuters
Read Next
Latest on Coronavirus
